IRIS
ARDIZZONI, Andrea
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 1.923
AS - Asia 1.680
EU - Europa 1.240
SA - Sud America 208
AF - Africa 110
OC - Oceania 6
Continente sconosciuto - Info sul continente non disponibili 1
Totale 5.168
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 1.879
CN - Cina 571
SG - Singapore 549
FI - Finlandia 268
VN - Vietnam 260
IE - Irlanda 197
SE - Svezia 197
IT - Italia 170
BR - Brasile 155
DE - Germania 140
HK - Hong Kong 108
TR - Turchia 68
FR - Francia 66
ZA - Sudafrica 64
NL - Olanda 48
GB - Regno Unito 47
IN - India 28
UA - Ucraina 28
CI - Costa d'Avorio 26
CA - Canada 25
AR - Argentina 21
PL - Polonia 20
RU - Federazione Russa 13
BD - Bangladesh 12
MX - Messico 12
JP - Giappone 10
PK - Pakistan 10
EC - Ecuador 8
ES - Italia 8
PH - Filippine 8
BE - Belgio 7
MA - Marocco 7
CO - Colombia 6
CZ - Repubblica Ceca 6
IQ - Iraq 6
JO - Giordania 6
LT - Lituania 6
AT - Austria 5
SA - Arabia Saudita 5
UZ - Uzbekistan 5
VE - Venezuela 5
AU - Australia 4
CL - Cile 4
ID - Indonesia 4
MY - Malesia 4
PY - Paraguay 4
EG - Egitto 3
KR - Corea 3
NP - Nepal 3
AL - Albania 2
AO - Angola 2
AZ - Azerbaigian 2
BB - Barbados 2
BY - Bielorussia 2
CY - Cipro 2
DO - Repubblica Dominicana 2
DZ - Algeria 2
ET - Etiopia 2
IR - Iran 2
KE - Kenya 2
LU - Lussemburgo 2
NZ - Nuova Zelanda 2
OM - Oman 2
PE - Perù 2
SI - Slovenia 2
SN - Senegal 2
TH - Thailandia 2
UY - Uruguay 2
AE - Emirati Arabi Uniti 1
BG - Bulgaria 1
BO - Bolivia 1
CR - Costa Rica 1
GE - Georgia 1
GR - Grecia 1
HN - Honduras 1
HU - Ungheria 1
KG - Kirghizistan 1
KZ - Kazakistan 1
LB - Libano 1
LK - Sri Lanka 1
MN - Mongolia 1
NO - Norvegia 1
PA - Panama 1
PS - Palestinian Territory 1
RO - Romania 1
RS - Serbia 1
TJ - Tagikistan 1
TW - Taiwan 1
XK - ???statistics.table.value.countryCode.XK??? 1
Totale 5.168
Salva come PNG Salva come JPEG
Città #
Singapore 306
Ashburn 268
Chandler 260
Dublin 197
Beijing 141
Dallas 136
San Jose 128
Santa Clara 120
Hong Kong 101
Ho Chi Minh City 82
New York 71
Parma 69
Nanjing 66
Dearborn 62
Johannesburg 60
Izmir 57
Munich 56
Shanghai 54
Boardman 53
Hanoi 53
Ann Arbor 39
Los Angeles 39
Jacksonville 36
Princeton 35
Lauterbourg 33
Abidjan 26
San Mateo 26
Bremen 25
Wilmington 24
Kunming 22
Jinan 20
Turku 20
Helsinki 19
São Paulo 19
Tianjin 18
Shenyang 17
Buffalo 16
Denver 16
Frankfurt am Main 16
Nanchang 15
Hefei 14
Warsaw 14
Da Nang 13
Haiphong 12
Jiaxing 12
Hebei 11
Seattle 11
Columbus 10
Toronto 10
Marseille 9
Guangzhou 8
Hangzhou 8
London 8
Rio Saliceto 8
Tokyo 8
Brussels 7
Council Bluffs 7
Leawood 7
Phoenix 7
Poplar 7
Zhengzhou 7
Biên Hòa 6
Brooklyn 6
Chennai 6
Haikou 6
Leipzig 6
Norwalk 6
Pune 6
Amman 5
Bexley 5
Chicago 5
Houston 5
Hải Dương 5
Moscow 5
New Delhi 5
Ottawa 5
Rio de Janeiro 5
The Dalles 5
Woodbridge 5
Amsterdam 4
Belo Horizonte 4
Changsha 4
Chengdu 4
City of London 4
Des Moines 4
Fuzhou 4
Mexico City 4
Montreal 4
Nuremberg 4
Quito 4
Rome 4
San Francisco 4
Stockholm 4
Taizhou 4
Wroclaw 4
Ankara 3
Bologna 3
Bắc Ninh 3
Curitiba 3
Genoa 3
Totale 3.195
Salva come PNG Salva come JPEG
Nome #
Isolation and characterization of circulating tumor cells in advanced squamous-cell carcinoma of the lung 206
Characterization of gefitinib uptake in NSCLC cell lines 189
Isolation and Characterization of Circulating Tumor Cells in Squamous Cell Carcinoma of the Lung Using a Non-EpCAM-Based Capture Method 184
Enhancement of the anti-tumor activity of FGFR1 inhibition in squamous cell lung cancer by targeting downstream signaling involved in glucose metabolism. 182
Trastuzumab emtansine is active on HER-2 overexpressing NSCLC cell lines and overcomes gefitinib resistance 180
Combination of Gefitinib and Pemetrexed Prevents the Acquisition of TKI Resistance in NSCLC Cell Lines Carrying EGFR-Activating Mutation 176
Epidermal growth factor receptor tyrosine kinase inhibitors: current status and future perspectives in the development of novel irreversible inhibitors for the treatment of mutant non-small cell lung cancer 172
Gefitinib inhibits invasive phenotype and epithelial-mesenchymal transition in drug-resistant NSCLC cells with MET amplification 169
Histological subtype analysis of colon cancer: a population-based study. Different sides and different diseases. 168
Effect of ABCG2/BCRP Expression on Efflux and Uptake of Gefitinib in NSCLC Cell Lines 166
ACCURACY OF CYTOLOGY IN THE IDENTIFICATION OF HISTOLOGIC SUBTYPE IN NON-SMALL CELL LUNG CANCER (NSCLC 165
Strong Notch activation hinders bevacizumab efficacy in advanced colorectal cancer 165
Cancer stem cells related marker CD44 and Notch activation in metastatic colon cancer patients 161
Neoplasie del polmone in Neoplasie del Distretto Toracico 159
ALK and ROS1 rearrangements tested by fluorescence in situ hybridization in cytological smears from advanced non-small cell lung cancer patients 157
Aberrant expression of PTEN in squamous lung cancer cells: molecular analysis and impact on the synergistic combination of the targeted therapy with BKM120 and Defactinib 156
Gefitinib metabolism by CYP1A1 affects biological responses in NSCLC cell lines. 155
Molecular mechanisms underlying the antitumor activity of 3-aminopropanamide irreversible inhibitors of the epidermal growth factor receptor in non-small cell lung cancer 153
Predictive factors of diagnostic accuracy of CT-guided transthoracic fine-needle aspiration for solid noncalcified, subsolid and mixed pulmonary nodules. 148
CT-guided biopsy of pulmonary nodules: Is pulmonary hemorrhage a complication or an advantage? 147
Epidermal Growth Factor Receptor Irreversible Inhibitors: Chemical Exploration of the Cysteine-Trap Portion 144
Notch Activation Modulates Bevacizumab Activity by CD44 Positive Cancer Stem Cells in Advanced Colon Cancer 143
Correlation between erlotinib pharmacokinetics, cutaneous toxicity and clinical outcomes in patients with advanced non-small cell lung cancer (NSCLC) 141
Reliability of EGFR and KRAS mutation analysis on fine-needle aspiration washing in non-small cell lung cancer 141
MYC Amplification as a Potential Mechanism of Primary Resistance to Crizotinib in ALK-Rearranged Non-Small Cell Lung Cancer: A Brief Report 139
INCREASED SOLUBLE AND MEMBRANE-BOUND PD-L1 EXPRESSION IN NSCLC CELL LINES TREATED WITH PEMETREXED 135
Grading the neuroendocrine tumors of the lung: an evidence-based proposal. 130
Predictive and prognostic value of early response assessment using 18FDG-PET in advanced non-small cell lung cancer patients treated with erlotinib 130
Targeting oncogenic PI3K/Akt/mTOR pathway in squamous cell lung carcinoma 120
Effect of dual PI3K and FAK inhibition in squamous lung carcinoma with reduced PTEN level 118
Role of cell gefitinib metabolism in the response of NSCLC cell lines to gefitinib. 113
Synergistic effect of PI3K and FAK inhibition in squamous lung cancer cells with reduced PTEN level 109
The maintenance of gefitinib inhibits migration and epithelial-mesenchimal transition of Non-small cell lung cancer cell lines that have become resistant after prolonged gefitinib treatment 104
Synergic anti-proliferative effect of gefitinib and RAD001 in non small cell lung cancer cell lines 99
Preclinical study assessing effects of gefitinib continuation after development of gefitinib resistance in NSCLC with activating EGFR mutations 90
Totale 5.214
Salva come PNG Salva come JPEG
Categoria #
all - tutte 16.290
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 16.290
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/202151 0 0 0 0 0 0 0 0 0 7 42 2
2021/2022120 1 1 1 12 2 0 5 15 9 9 8 57
2022/2023805 70 113 57 63 73 102 5 54 239 0 21 8
2023/2024279 12 21 6 9 24 92 20 18 11 6 14 46
2024/2025953 37 37 51 67 116 92 24 33 144 69 97 186
2025/20261.881 227 175 199 212 308 130 159 78 262 131 0 0
Totale 5.214